Literature DB >> 15297863

Prospective survey of adverse reactions to topical antiglaucoma medications in a hospital population.

R Bhatt1, K W Whittaker, S Appaswamy, A Desai, A Fitt, S Sandramouli.   

Abstract

AIM: To identify the relative incidence and profile of adverse drug reaction (ADR) to various topical ocular hypotensives in a hospital setting.
METHODS: All the patients presenting in outpatients clinic and accident and emergency with an ADR to topical hypotensive agent from August 2000 to January 2001 were included in the study. Details regarding the type date of commencing the treatment, the date of developing ADR, time to resolution of the ADR were noted.
RESULTS: Over the period of 6 months, 66 patients presented with 73 ADRs. Brimonidine was the most frequent offending agent. In total, 23 (34.8%) presented with ADR after being commenced on treatment for more than 12 months. In all, 16 (24%) patients had IOP > 21 on presentation, eight (12%) patients underwent filtration surgery following the development of ADR.
CONCLUSION: Adverse drug reaction to ocular hypotensive agents is not uncommon and can have a major impact on glaucoma management. Delayed presentation and association with raised intraocular pressure presentation emphasise the need for effective patient education to encourage prompt reporting of ADR.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15297863     DOI: 10.1038/sj.eye.6701515

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  3 in total

1.  Formulation to target delivery to the ciliary body and choroid via the suprachoroidal space of the eye using microneedles.

Authors:  Yoo Chun Kim; Kyung Hee Oh; Henry F Edelhauser; Mark R Prausnitz
Journal:  Eur J Pharm Biopharm       Date:  2015-05-31       Impact factor: 5.571

Review 2.  Targeting drug delivery within the suprachoroidal space.

Authors:  Jae Hwan Jung; J Jeremy Chae; Mark R Prausnitz
Journal:  Drug Discov Today       Date:  2019-04-03       Impact factor: 7.851

3.  Targeted delivery of antiglaucoma drugs to the supraciliary space using microneedles.

Authors:  Yoo C Kim; Henry F Edelhauser; Mark R Prausnitz
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-09-11       Impact factor: 4.799

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.